Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
- FMC Named Among Newsweek Magazine’s “Most Loved Workplaces” Posted 11-12-2021
- The Future Of Kidney Care At Home Posted 11-12-2021
- Outset Medical Beat Q2 Wall Street Projections Posted 09-14-2021
- Fresenius Invests to Help Humacyte Develop Implantable Blood Vessels Posted 09-14-2021